Aleniglipron for Diabetes

(GSBR-1290 Trial)

Recruiting at 13 trial locations

Overseen By Medical Director

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Must not be taking: Glucose-interfering drugs

Disqualifiers: Diabetic retinopathy, Obesity surgery, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 38 weeks

50 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

Are You a Good Fit for This Trial?

Inclusion Criteria

Have a BMI ≥27.0 kg/m2

Signed Informed Consent

I have been diagnosed with type 2 diabetes for 6 months or more.

Exclusion Criteria

I have lost or gained more than 11 pounds in the last 3 months.

I have had or am planning to have surgery for obesity, not including liposuction or tummy tuck if done over a year ago.

I am being treated for eye problems due to diabetes and have had an eye exam in the last year.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive aleniglipron or placebo orally once daily

38 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Aleniglipron

How Is the Trial Designed?

Group I: Arm 2: Participants will receive a placebo administered orally Experimental Treatment 1 Intervention

Drug placebo administered orally

Group II: Arm 1: Participants will receive aleniglipron administered orally Experimental Treatment 1 Intervention

Drug aleniglipron administered orally

Who Is Running the Clinical Trial?

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Lead Sponsor

Trials

5

Recruited

530+